医学
肝细胞癌
内科学
糖尿病
阿司匹林
队列
人口
危险系数
脂肪变性
比例危险模型
肝癌
风险因素
胃肠病学
内分泌学
置信区间
环境卫生
作者
Xianhua Mao,Ka Shing Cheung,Jing‐Tong Tan,Lung‐Yi Mak,Chi‐Ho Lee,Chi‐Leung Chiang,Ho‐Ming Cheng,Rex Wan‐Hin Hui,Wai K. Leung,Man‐Fung Yuen,Wai‐Kay Seto
摘要
BACKGROUND: Optimal glycaemic control has well-established health benefits in patients with diabetes mellitus (DM). It is uncertain whether optimal glycaemic control can benefit liver-related outcomes. AIMS: To examine the association of optimal glycaemic control with hepatocellular carcinoma (HCC) and liver-related mortality. METHODS: In a population-based cohort, we identified patients with newly diagnosed DM between 2001 and 2016 in Hong Kong. Optimal glycaemic control was defined as mean haemoglobin A1c (HbA1c) <7% during the 3-year lead-in period after DM diagnosis. By applying propensity score matching to balance covariates, we analysed glycaemic control via competing risk models with outcomes of interest being HCC and liver-related mortality. RESULTS: (SHR 0.63-0.75), smoking (SHR 0.61-0.72), hepatic steatosis (SHR 0.67-0.68) and aspirin/statin/metformin use (SHR 0.67-0.75). A lower risk of liver-related mortality in relation to optimal glycaemic control was also observed (SHR 0.70, 95% CI 0.61-0.80). CONCLUSIONS: Glycaemic control is an independent risk factor for HCC and liver-related mortality, and should be incorporated into oncoprotective strategies in the general DM population.
科研通智能强力驱动
Strongly Powered by AbleSci AI